Patent disclosure requirements for therapeutic antibody patents.
Therapeutic antibodies have grown to become an important product class within the biopharmaceutical market. A prerequisite to their commercialization is adequate patent protection. Disclosure requirements and the types of claims available in different jurisdictions can impact the scope of protection available for antibodies. Areas covered: A comparative review of statutory bases, patent office practices and selected decisions in Canada, the United States and the United Kingdom related to disclosure requirements is provided. Expert opinion: Differences in disclosure requirements exist in different jurisdictions which can impact the type of claims obtained and their survival when attacked in litigation. Including a wide variety of claim types is a key strategy to ensuring therapeutic antibodies are adequately protected. Method of use claims may provide advantages and broader protection in some circumstances and should also be considered.
['De Luca|Carmela|C|', 'Trifonova|Anastassia|A|']
D000818:Animals D000906:Antibodies D002170:Canada D030881:Disclosure D006801:Humans D007880:Legislation, Drug D010330:Patents as Topic D006113:United Kingdom D014481:United States
disclosure requirements Therapeutic antibodies patent protection Canada United States and United Kingdom sufficiency support requirements